Specialised Therapeutics Australia announced that a phase III clinical trial of breast cancer drug ABRAXANE® (nanoparticle albumin-bound paclitaxel) in combination with current standard of care gemcitabine in patients with advanced pancreatic cancer has demonstrated substantially improved survival t more
To use all functions of this page, please activate cookies in your browser.
